DBV Technologies Soars After Positive Phase 3 Trial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 23 2024
0mins
Should l Buy DBVT?
Source: Newsfilter
DBV Technologies S.A. experienced a significant price increase of 44.61%, reaching a 52-week high, following the announcement of positive results from its Phase 3 VITESSE trial for the VIASKIN Peanut patch.
The surge is attributed to the successful Phase 3 VITESSE trial results for the VIASKIN Peanut patch, which demonstrated a 46.6% response rate among children, significantly higher than the 14.8% in the placebo group. This success not only highlights the clinical relevance of the treatment but also sets the stage for a Biologics License Application (BLA) submission to the FDA in early 2026, with expectations for priority review.
This positive trial outcome has reinvigorated investor interest in DBV Technologies, reflecting optimism about the company's future in the peanut allergy treatment market, especially given the favorable safety profile and the potential for substantial funding to support further development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DBVT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DBVT
Wall Street analysts forecast DBVT stock price to rise
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.990
Low
40.00
Averages
46.40
High
51.00
Current: 20.990
Low
40.00
Averages
46.40
High
51.00
About DBVT
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. It dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The Company's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The Company operates one subsidiary DBV Technologies Inc. in the United States.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
DBV Technologies' VIASKIN Peanut Patch Achieves Phase 3 Trial Success
- Clinical Trial Success: DBV Technologies' VIASKIN peanut patch met its primary endpoint in the pivotal Phase 3 VITESSE trial, demonstrating significant desensitization in children aged 4 to 7, addressing the urgent need for safe and effective therapies.
- Efficacy Data: 46.6% of children in the treatment group were responders at 12 months compared to only 14.8% in the placebo group, indicating a significant advantage in increasing children's tolerance thresholds.
- Good Safety Profile: The therapy was generally well tolerated, with most adverse events limited to mild localized skin reactions, demonstrating its safety and acceptability in clinical applications.
- Future Plans: DBV Technologies plans to submit a Biologics License Application (BLA) to the U.S. FDA in the first half of 2026, and if approved, the VIASKIN peanut patch could become the first non-invasive, patch-based therapy for peanut allergy, presenting significant market potential.
See More
DBV Technologies Presents Positive Data from VIASKIN® Peanut Patch Study
- Clinical Trial Success: At the AAAAI 2026 Annual Meeting, DBV Technologies presented data from the Phase 3 VITESSE study of the VIASKIN® Peanut Patch, showing that 83% of children increased their eliciting dose at 12 months compared to 48% in the placebo group, indicating significant efficacy of this treatment in peanut-allergic children.
- Significant Treatment Effect: Among the treated group, 46.6% of children met the treatment responder criteria at 12 months, compared to only 14.8% in the placebo group, with a difference of 31.8%, exceeding the pre-specified threshold of 15%, thus laying a solid foundation for future FDA applications.
- Good Safety Profile: The VIASKIN® Peanut Patch was well tolerated, with the majority of treatment-emergent adverse events being mild local reactions, consistent with DBV's previous Phase 3 studies, demonstrating the product's safety in clinical applications.
- Huge Market Potential: If approved, the VIASKIN® Peanut Patch would provide a non-invasive treatment option for peanut-allergic children that fits into daily activities, with DBV planning to submit a Biologics License Application to the FDA in the first half of this year, further advancing its market entry.
See More
DBV Technologies to Present VIASKIN® Data at AAAAI 2026
- Research Data Presentation: DBV Technologies will present additional data from the VITESSE Phase 3 study of the VIASKIN® Peanut Patch for children aged 4-7 at the 2026 AAAAI Annual Meeting, which is expected to enhance market awareness and trust in the product.
- Expert Panel Discussion: During the conference, a panel discussion on the potential of epicutaneous immunotherapy (EPIT) will explore the impact of early intervention in children with peanut allergies, potentially driving the adoption of new treatment options.
- Oral Abstract Presentation: DBV will deliver an oral abstract presentation on February 28, detailing the efficacy and safety of EPIT in peanut-allergic children, further validating its clinical application effectiveness.
- Exhibition Participation: DBV will exhibit at booth #1527 at the AAAAI conference, attracting attendees to learn about the latest developments in EPIT, which may facilitate the company's market share growth in food allergy treatment.
See More
DBV Technologies to Participate in Biotech Summit
- Executive Participation: DBV Technologies CEO Daniel Tassé will participate in a fireside chat at the Guggenheim Securities Biotech Summit on February 12, 2026, at 2:30 PM in New York, showcasing the company's advancements in biopharmaceuticals and likely attracting investor interest.
- Technological Innovation: DBV is focused on developing its proprietary VIASKIN® patch technology to address food allergies and other immunologic conditions, aiming to introduce microgram amounts of biologically active compounds through the skin to retrain the immune system, providing new treatment options for millions of allergy sufferers.
- Clinical Trial Progress: The company is currently conducting clinical trials of the VIASKIN® Peanut patch for peanut-allergic toddlers and children aged 1 to 7 years, demonstrating its commitment and potential to meet significant unmet medical needs in the allergy treatment space.
- Market Positioning and Growth: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on Nasdaq, reflecting its strategic positioning in the global market.
See More
Total Voting Rights and Shares as of January 31, 2026
- Total Shares: As of January 31, 2026, the company has a total of 274,852,082 shares, indicating stability in the market and a broad shareholder base, which may positively impact future financing activities.
- Total Voting Rights: The total voting rights on the same date amount to 274,852,082, reflecting transparency in the company's governance structure and ensuring equal voice for all shareholders in major decisions, thereby enhancing investor confidence.
- Net Voting Rights: The net voting rights stand at 274,792,237 shares, indicating that a small portion of shares lacks voting rights, which may affect the actual influence of shareholders in corporate governance.
- Compliance Information: This information complies with Article 223-16 of the French Financial Markets Authority (AMF) regulations, ensuring the company's adherence to disclosure requirements, which helps to build market trust in the company.
See More
DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
- Successful Financing: DBV Technologies raised €166.7 million through the full exercise of 34,090,004 ABSA warrants and 71,005,656 BS warrants, ensuring sufficient operational funding for the next 12 months to support the upcoming commercial launch of the VIASKIN® Peanut patch.
- Dilution Impact: Following this financing, the company's shareholder equity per share decreased from €0.53 to €0.46, with ownership interest dropping from 1% to 0.78%, highlighting the dilution effect on existing shareholders while providing necessary funding for future product launches.
- Market Entry Plans: Proceeds will be utilized for preparing and submitting a Biologics License Application (BLA) and planning the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new treatment options for children aged 4 to 7, addressing urgent market needs for food allergy treatments.
- Future Outlook: DBV Technologies anticipates that if all outstanding warrants are exercised, total financing could reach €284.5 million, further enhancing the company's financial stability and competitive position in the biopharmaceutical sector for long-term growth.
See More
DBV Technologies' VIASKIN Peanut Patch Achieves Phase 3 Trial Success
- Clinical Trial Success: DBV Technologies' VIASKIN peanut patch met its primary endpoint in the pivotal Phase 3 VITESSE trial, demonstrating significant desensitization in children aged 4 to 7, addressing the urgent need for safe and effective therapies.
- Efficacy Data: 46.6% of children in the treatment group were responders at 12 months compared to only 14.8% in the placebo group, indicating a significant advantage in increasing children's tolerance thresholds.
- Good Safety Profile: The therapy was generally well tolerated, with most adverse events limited to mild localized skin reactions, demonstrating its safety and acceptability in clinical applications.
- Future Plans: DBV Technologies plans to submit a Biologics License Application (BLA) to the U.S. FDA in the first half of 2026, and if approved, the VIASKIN peanut patch could become the first non-invasive, patch-based therapy for peanut allergy, presenting significant market potential.
See More
DBV Technologies Presents Positive Data from VIASKIN® Peanut Patch Study
- Clinical Trial Success: At the AAAAI 2026 Annual Meeting, DBV Technologies presented data from the Phase 3 VITESSE study of the VIASKIN® Peanut Patch, showing that 83% of children increased their eliciting dose at 12 months compared to 48% in the placebo group, indicating significant efficacy of this treatment in peanut-allergic children.
- Significant Treatment Effect: Among the treated group, 46.6% of children met the treatment responder criteria at 12 months, compared to only 14.8% in the placebo group, with a difference of 31.8%, exceeding the pre-specified threshold of 15%, thus laying a solid foundation for future FDA applications.
- Good Safety Profile: The VIASKIN® Peanut Patch was well tolerated, with the majority of treatment-emergent adverse events being mild local reactions, consistent with DBV's previous Phase 3 studies, demonstrating the product's safety in clinical applications.
- Huge Market Potential: If approved, the VIASKIN® Peanut Patch would provide a non-invasive treatment option for peanut-allergic children that fits into daily activities, with DBV planning to submit a Biologics License Application to the FDA in the first half of this year, further advancing its market entry.
See More
DBV Technologies to Present VIASKIN® Data at AAAAI 2026
- Research Data Presentation: DBV Technologies will present additional data from the VITESSE Phase 3 study of the VIASKIN® Peanut Patch for children aged 4-7 at the 2026 AAAAI Annual Meeting, which is expected to enhance market awareness and trust in the product.
- Expert Panel Discussion: During the conference, a panel discussion on the potential of epicutaneous immunotherapy (EPIT) will explore the impact of early intervention in children with peanut allergies, potentially driving the adoption of new treatment options.
- Oral Abstract Presentation: DBV will deliver an oral abstract presentation on February 28, detailing the efficacy and safety of EPIT in peanut-allergic children, further validating its clinical application effectiveness.
- Exhibition Participation: DBV will exhibit at booth #1527 at the AAAAI conference, attracting attendees to learn about the latest developments in EPIT, which may facilitate the company's market share growth in food allergy treatment.
See More
DBV Technologies to Participate in Biotech Summit
- Executive Participation: DBV Technologies CEO Daniel Tassé will participate in a fireside chat at the Guggenheim Securities Biotech Summit on February 12, 2026, at 2:30 PM in New York, showcasing the company's advancements in biopharmaceuticals and likely attracting investor interest.
- Technological Innovation: DBV is focused on developing its proprietary VIASKIN® patch technology to address food allergies and other immunologic conditions, aiming to introduce microgram amounts of biologically active compounds through the skin to retrain the immune system, providing new treatment options for millions of allergy sufferers.
- Clinical Trial Progress: The company is currently conducting clinical trials of the VIASKIN® Peanut patch for peanut-allergic toddlers and children aged 1 to 7 years, demonstrating its commitment and potential to meet significant unmet medical needs in the allergy treatment space.
- Market Positioning and Growth: Headquartered in Châtillon, France, with North American operations in Warren, NJ, DBV's ordinary shares are traded on Euronext Paris while its ADSs are listed on Nasdaq, reflecting its strategic positioning in the global market.
See More
Total Voting Rights and Shares as of January 31, 2026
- Total Shares: As of January 31, 2026, the company has a total of 274,852,082 shares, indicating stability in the market and a broad shareholder base, which may positively impact future financing activities.
- Total Voting Rights: The total voting rights on the same date amount to 274,852,082, reflecting transparency in the company's governance structure and ensuring equal voice for all shareholders in major decisions, thereby enhancing investor confidence.
- Net Voting Rights: The net voting rights stand at 274,792,237 shares, indicating that a small portion of shares lacks voting rights, which may affect the actual influence of shareholders in corporate governance.
- Compliance Information: This information complies with Article 223-16 of the French Financial Markets Authority (AMF) regulations, ensuring the company's adherence to disclosure requirements, which helps to build market trust in the company.
See More
DBV Technologies Secures €166.7 Million Financing to Support VIASKIN® Peanut Patch Launch
- Successful Financing: DBV Technologies raised €166.7 million through the full exercise of 34,090,004 ABSA warrants and 71,005,656 BS warrants, ensuring sufficient operational funding for the next 12 months to support the upcoming commercial launch of the VIASKIN® Peanut patch.
- Dilution Impact: Following this financing, the company's shareholder equity per share decreased from €0.53 to €0.46, with ownership interest dropping from 1% to 0.78%, highlighting the dilution effect on existing shareholders while providing necessary funding for future product launches.
- Market Entry Plans: Proceeds will be utilized for preparing and submitting a Biologics License Application (BLA) and planning the launch of the VIASKIN® Peanut patch in the U.S., which, if approved, will offer new treatment options for children aged 4 to 7, addressing urgent market needs for food allergy treatments.
- Future Outlook: DBV Technologies anticipates that if all outstanding warrants are exercised, total financing could reach €284.5 million, further enhancing the company's financial stability and competitive position in the biopharmaceutical sector for long-term growth.
See More
